Project-004

项目-004

基本信息

批准号：
9353044
负责人：
JOHN MORRIS
金额：
$ 37.59万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2005
资助国家：
美国
起止时间：
2005-09-30 至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/9353044
关键词：
Adult Children Alzheimer&apos s Disease Amyloid Amyloid Proteins Amyloid deposition Atrophic Binding Biological Markers Biostatistics Core Brain Brain Mapping Brain imaging Cerebrospinal Fluid Classification Clinical Clinical Treatment Clinical Trials Clinical Trials Design Cognition Cognitive Collaborations Data Dementia Deposition Development Diffusion Diffusion Magnetic Resonance Imaging Disease Elderly Evaluation Family history of Future Genotype Hippocampus (Brain)Image Imaging Techniques Impaired cognition Individual Magnetic Resonance Imaging Maps Measures Modality Modeling Neuronal Dysfunction Participant Pathology Pattern Positron-Emission Tomography Program Research Project Grants Rest Risk Role Scanning Seeds Staging Structure Surface Symptoms Techniques Temporal Lobe Testing Thick TimeLine United States Food and Drug Administration VSNL1 gene Work apolipoprotein E-4 attentional control base brain health data management functional loss gray matter imaging biomarker improved neurogranin novel novel strategies novel therapeutics pre-clinical spectrograph tau Proteins therapy design uptake white matter

项目摘要

The Adult Children Study (ACS) is an ongoing evaluation of middle to older adults at risk for development of Alzheimer disease (AD). In Project 4 of the ACS, we use a combination of advanced imaging techniques to explore the earliest signs of AD pathology. Using positron emission tomography (PET) we test for amyloid protein deposits in the brain, which can be present up to 20 years before dementia symptoms are present. We will do this using florbetapir F18, which is a test for amyloid which has approval by the Federal Food and Drug Administration (FDA). Using magnetic resonance imaging (MRI) we evaluate the functional changes in the brain associated with the transition from the asymptomatic (preclinical) stages of AD into the symptomatic stage of AD dementia. We also use MRI to evaluate the brain’s structure, looking at grey matter atrophy with volumetric MRI, and investigate the changes in white matter using a new technique, diffusion basis spectrum imaging (DBSI). In collaboration with Project 4, in Aim 1, we will generate unique brain maps for each imaging test, in each stage of AD, as people move from an asymptomatic state into AD dementia. In Aim 2, we will then examine these maps in relation to one another, to develop an integrated timeline for the imaging changes which occur during the transition from asymptomatic and symptomatic AD. We will then use these maps as a way to predict the stage of the disease in specific individuals – in other words, to predict how long it would be before someone developed dementia. This mapping and predictive information is critical for the development of new drugs for AD and for the appropriate design of clinical trials in the future.

成人儿童研究 (ACS) 是一项针对具有发展风险的中老年人的持续评估在 ACS 项目 4 中，我们结合使用先进的成像技术来诊断阿尔茨海默病 (AD)。我们使用正电子发射断层扫描 (PET) 检测淀粉样蛋白，探索 AD 病理学的最早迹象。大脑中的蛋白质沉积物可能在痴呆症状出现前 20 年就已存在。将使用florbetapir F18来做到这一点，这是一种淀粉样蛋白测试，已获得联邦食品和药物管理局的批准管理（FDA）。我们使用磁共振成像（MRI）评估功能变化。大脑与 AD 从无症状（临床前）阶段过渡到有症状阶段相关我们还使用 MRI 来评估大脑的结构，观察灰质萎缩情况。体积 MRI，并使用扩散基谱新技术研究白质的变化与项目 4 合作，在目标 1 中，我们将为每个成像生成独特的脑图。测试，在 AD 的每个阶段，当人们从无症状状态转变为 AD 痴呆时，我们将进行目标 2。然后检查这些图的相互关系，为成像变化制定一个综合的时间表然后，我们将使用这些图作为从无症状 AD 到有症状 AD 的过渡期间发生的情况。预测特定个体疾病阶段的方法——换句话说，预测疾病会持续多久在某人患上痴呆症之前，这种映射和预测信息对于发展至关重要。 AD 新药的研发以及未来临床试验的适当设计。